Joint committee advances bill to cap insulin copays at $35 for 30-day supply

At a joint hearing of the Nevada Assembly and Senate Commerce and Labor committees in Carson City, lawmakers advanced Assembly Bill 555, a proposal to cap out-of-pocket costs for prescription insulin at no more than $35 for a 30‑day supply for privately insured Nevadans.

The bill’s sponsor, Assemblymember Steve Yeager, said the measure would spare families and individuals from choosing between insulin and basic needs. "Nevadans should never have to sacrifice life saving medication because it is not affordable," Yeager said during his presentation.

Supporters — including health-care provider groups, patient advocates and business associations — told the committees the cap will reduce insulin rationing and prevent costly complications. Davida Tyson of the Nevada Women’s Lobby said families are sometimes forced to choose between medication and groceries. "When insulin becomes financially inaccessible, families are forced to make impossible choices," she said. The Nevada State Medical Association and retail pharmacy representatives also testified in support, saying predictable copays could reduce emergency care and improve workforce stability.

Opponents and neutral witnesses raised implementation and market‑effect concerns. Wizz Rousard of Americans for Prosperity argued state price caps risk further market distortion and urged federal action instead, saying, "This proposal should be more of a joint resolution rather than a state law." The Nevada Association of Health Plans and other insurers said the bill lowers member cost sharing but does not address manufacturers’ prices and could shift costs onto premiums or the broader risk pool.

Officials from the Division of Insurance provided technical context about enforcement and market oversight. Adam Plaine of the Division of Insurance told the committees the division would use its existing review and consumer‑complaint processes and could pursue escalating remedies. "If it turns out to be a pervasive problem with a particular insurer . . . the division can call a targeted market conduct examination" under existing authority and, where appropriate, pursue fines or revocation of a certificate of authority, Plaine said.

Key provisions described by Yeager would prohibit certain private insurers from imposing a deductible, copayment, coinsurance or other cost sharing greater than $35 for a 30‑day supply of prescription insulin. The bill’s text, as presented, excludes Medicaid recipients, children’s health insurance program (CHIP) beneficiaries, and state and local government employee health plans from the cap; Yeager and staff said the intent is to apply the cap to private commercial insurance only.

Committee members asked about scope and effects. Vice Chair Houdegui asked whether the cap would apply to a cash purchaser; Yeager said it would not, because the bill governs insurance contracts, not pharmacy cash prices. Senator Flores asked how enforcement would proceed after the measure’s effective date; Yeager and Division of Insurance staff said enforcement would rely on insurer filings and consumer complaints, with the division able to require corrections and, in extreme cases, suspend or revoke an insurer’s certificate of authority.

The committees also heard prevalence and cost figures cited by the sponsor and witnesses: Yeager cited American Diabetes Association and federal data (about 38 million Americans with diabetes), and estimated roughly 250,900 diagnosed adults in Nevada (about 8.8% of adults). He said insulin prices have produced individual costs as high as $500 per month in some cases and pointed to the federal Inflation Reduction Act’s $35 monthly cap for insulin under Medicare Part D as a precedent.

After the hearing, the committee held a work session. Speaker Yeager formally waived the customary 24‑hour waiting period under committee rules. A motion "to do pass" Assembly Bill 555 was made (first by Vice Chair Houdegui and seconded by Assemblymember O'Neil) and the chair called the voice vote; the motion carried and the measure was reported out of committee to the full floor. The committee record assigns the floor statement to Vice Chair Houdegui.

Votes at a glance: the committee approved a motion to report AB 555 out of committee by voice vote; the transcript records the chair’s announcement "Motion carries" but does not record a roll‑call tally in the hearing transcript.

What happens next: the measure was reported to the floor with the committee’s recommendation that it do pass. Division of Insurance staff said plan filings for the 2026 plan year would be the mechanism to implement required changes for affected individual and small‑group policies; education and outreach to beneficiaries would follow through sponsor networks and advocacy groups, as discussed during testimony.